Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study

摘要: Background  Acitretin is available for use in psoriasis since the late 1980s; however, there no consensus on its optimum effective dose with acceptable side-effects. Objective  To evaluate efficacy and safety of acitretin three fixed doses adult patients severe plaque type psoriasis. Methods  This was a randomized, double blind, parallel group, ranging study. The study included either gender (age range, 18–65 years) chronic psoriasis. Of 80 screened, 61 were randomly assigned to groups: group A – 20 (acitretin 25 mg/day), B 35 mg/day) C 21 50 mg/day) 12 weeks. Forty-eight completed main outcome measure change Psoriasis Area Severity Index (PASI) score between groups from baseline 12 weeks. Results  After 12 weeks therapy, percentage reduction PASI 54%, 76% 54% 25, 35 50 mg/day respectively. 75 achieved 47%, 69% 53% majority adverse events mucocutaneous, mild-to-moderate severity dependent. Conclusions  35 mg/day observed be more efficacious compared 25 mg/day dosing, whereas profile better than dosing management patients.